GridAI Technologies (GRDX) Non-Current Debt (2019 - 2024)

GridAI Technologies' (GRDX) quarterly Non-Current Debt came in at $6.4 million in Q1 2024, up 1743.34% on a QoQ basis from $347082.0 in Q1 2021.

GridAI Technologies (GRDX) Non-Current Debt (2019 - 2024) Analysis & Trends

GridAI Technologies (GRDX) has 4 years of Non-Current Debt data on file, last reported at $6.4 million in Q1 2024.

Quarterly Non-Current Debt changed N/A year-over-year to $6.4 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $6.4 million (changed N/A YoY) and the FY2019 annual result came in at $444364.0, changed N/A from the prior year.
Non-Current Debt grew to $6.4 million in Q1 2024, from $347082.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $6.4 million in Q1 2024 to a low of $112609.0 in Q2 2020.
A 3-year average of $1.8 million and a median of $313349.0 in 2020 frame the typical range for Non-Current Debt.
The widest YoY moves for Non-Current Debt: up 24.13% in 2021, down 24.13% in 2021.
Tracing GRDX's Non-Current Debt over 3 years: stood at $112609.0 in 2020, then soared by 208.22% to $347082.0 in 2021, then surged by 1743.34% to $6.4 million in 2024.
The last three Non-Current Debt figures came in at $6.4 million (Q1 2024), $347082.0 (Q1 2021), and $112609.0 (Q2 2020), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	GridAI Technologies	5.82 Mn	5.82 Mn	-	-

Download Data